Niagen Bioscience, Inc. revenue by segment NAGE

Annual Quarterly

Niagen Bioscience, Inc. splits its revenue 2 ways in its filings. By operating segments, the largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was Consumer Products at $23.3 million, 86% of the total. By sales mix, the largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was Consumer Products at $23.3 million, 86% of the total.

USD in millions. The percent under a figure is the change from the same quarter a year earlier.

Line	TTM Sep 30, 2026	Q3 FY2026 Sep 30, 2026	Q2 FY2026 Jun 30, 2026	Q1 FY2026 Mar 31, 2026	Q4 FY2025 Dec 31, 2025	Q3 FY2025 Sep 30, 2025	Q2 FY2025 Jun 30, 2025	Q1 FY2025 Mar 31, 2025	Q4 FY2024 Dec 31, 2024
Revenue	122	27	30	31	34	34	31	30	29
Operating segments
Consumer Products	—	23 -10.4% share 85.8%	24 +6.4% share 81.1%	22 +4.2% share 71.2%	—	26 share 76.6%	23 share 72.9%	22 share 70.5%	—
Ingredients	—	4 -47.2% share 14.0%	5 -29.3% share 18.1%	9 +4.8% share 27.2%	—	7 share 21.2%	8 share 24.5%	8 share 26.8%	—
Corporate And Reconciling Items	—	0 share 0.3%	0 share 0.8%	0 share 0.2%	—	—	—	—	—
Sales mix
Consumer Products	—	23 -10.4% share 85.8%	24 +6.4% share 81.1%	22 +4.2% share 71.2%	—	26 share 76.6%	23 share 72.9%	22 share 70.5%	—
Ingredients	—	4 -47.2% share 14.0%	5 -29.3% share 18.1%	9 +4.8% share 27.2%	—	7 share 21.2%	8 share 24.5%	8 share 26.8%	—
Corporate And Reconciling Items	—	0 share 0.3%	0 share 0.8%	0 share 0.2%	—	—	—	—	—

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: Medicinal Chemicals & Botanical Products (SIC 2833)
Listed as: NAGE (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Los Angeles, CA
SEC filer status: Large accelerated filer
SEC CIK: 1386570
Former names: ChromaDex Corp. (until Mar 10, 2025); CODY RESOURCES, INC. (until Jun 24, 2008)

Other Medicinal Chemicals & Botanical Products companies

All 43 Medicinal Chemicals & Botanical Products companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.